Zymeworks (ZYME) Long-Term Deferred Tax (2021 - 2026)
Zymeworks (ZYME) posted Long-Term Deferred Tax of $4.7 million for Q1 2026, little changed sequentially from $4.7 million in Q4 2025, and down 2.93% YoY from $4.8 million in Q1 2025.
Analysis
Zymeworks (ZYME) Long-Term Deferred Tax (2021 - 2026) Analysis & Trends
Zymeworks has reported Long-Term Deferred Tax for 6 years, with the latest figure at $4.7 million in Q1 2026.
- Quarterly Long-Term Deferred Tax fell 2.93% year-over-year to $4.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.7 million (down 2.93% YoY) and the FY2025 annual result came in at $4.7 million, up 7.34% from the prior year.
- Long-Term Deferred Tax steadied at $4.7 million in Q1 2026 per ZYME's latest filing, from $4.7 million in the prior quarter.
- Over five years, Long-Term Deferred Tax peaked at $4.9 million in Q3 2025 and troughed at $1.3 million in Q3 2023.
- A 5-year average of $3.5 million and a median of $3.9 million in 2024 frame the typical range for Long-Term Deferred Tax.
- The sharpest annual moves came in 2023 and 2024: Long-Term Deferred Tax sank 56.57% in 2023, then jumped 219.85% in 2024.
- Over 5 years, Long-Term Deferred Tax stood at $1.3 million in 2022, then jumped by 168.77% to $3.6 million in 2023, then climbed by 21.3% to $4.4 million in 2024, then increased by 7.34% to $4.7 million in 2025, then changed by 0.0% to $4.7 million in 2026.
- According to Business Quant data, Long-Term Deferred Tax over the past three periods registered $4.7 million, $4.7 million, and $4.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Zymeworks | 2.13 Bn | 1.86 Bn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 4.35 Mn |
| Mar 31, 2026 | 4.71 Mn |
| Dec 31, 2025 | 4.71 Mn |
| Sep 30, 2025 | 4.86 Mn |
| Jun 30, 2025 | 4.77 Mn |
| Mar 31, 2025 | 4.85 Mn |
| Dec 31, 2024 | 4.39 Mn |
| Sep 30, 2024 | 4.21 Mn |
| Jun 30, 2024 | 3.95 Mn |
| Mar 31, 2024 | 3.70 Mn |
| Dec 31, 2023 | 3.62 Mn |
| Sep 30, 2023 | 1.32 Mn |
| Jun 30, 2023 | 1.36 Mn |
| Mar 31, 2023 | 1.41 Mn |
| Dec 31, 2022 | 1.35 Mn |
| Sep 30, 2022 | 3.03 Mn |
| Dec 31, 2021 | 3.07 Mn |